(2) what representations he has received in the last 12 months on the issue of the availability of access to (a) dasatinib and (b) nilotinib for the treatment of chronic myeloid leukaemia; how many representations were received from (i) clinicians, (ii) patients and (iii) others; what the content was of the representations; and if he will make a statement.
The Department has held no discussions with Surrey primary care trust on making available the treatments dasatinib and nilotinib to patients with imatinib-resistant chronic myeloid leukaemia. It is for primary care trusts (PCTs) locally to decide whether to make these treatments available to patients.
The Department has received various correspondence from clinicians, patients and others about dasatinib and nilotinib. This correspondence mainly raises issues of access to dasatinib and nilotinib and the possibility of their appraisal by the National Institute for Health and Clinical Excellence (NICE).
My right hon. Friend the Minister of State, Department of Health, my right hon. Friend the Member for Bristol, South (Dawn Primarolo), is minded to refer dasatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia as part of the 17th wave of referrals to NICE. NICE has consulted with stakeholders on the remits and scopes for this appraisal. The Minister of State will make a final decision on whether to refer the topic to NICE following the outcome of NICE’s consultation.
No assessment has been made of the variations between primary care trust areas in patients' ability to access the treatments dasatinib and nilotinib for imatinib-resistant chronic myeloid leukaemia.
However, Ministers are minded to refer dasatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia to the National Institute for Health and Clinical Excellence (NICE) as part of the 17th work programme. NICE has consulted stakeholders on the remits and scopes for this appraisal. Ministers will make a final decision on whether to refer the topic to NICE following the outcome of NICE's consultation.